Reviewing Aurinia Pharmaceuticals (NASDAQ:AUPH) and Madrigal Pharmaceuticals (NASDAQ:MDGL)

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Risk and Volatility

Aurinia Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500.

Valuation & Earnings

This table compares Aurinia Pharmaceuticals and Madrigal Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05 million	7.76	$287.20 million	$2.29	7.21
Madrigal Pharmaceuticals	$958.40 million	10.84	-$288.28 million	($12.89)	-34.89

Aurinia Pharmaceuticals has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aurinia Pharmaceuticals and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Insider & Institutional Ownership

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Aurinia Pharmaceuticals and Madrigal Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	3	2	1	2.67
Madrigal Pharmaceuticals	1	2	15	0	2.78

Aurinia Pharmaceuticals currently has a consensus price target of $17.67, suggesting a potential upside of 7.01%. Madrigal Pharmaceuticals has a consensus price target of $699.20, suggesting a potential upside of 55.47%. Given Madrigal Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.

Summary

Aurinia Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.